Biosimilars

Brain Cancer

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Chronic Lymphocytic Leukemia

Colorectal Cancer

Disparities in Cancer Care

Gastrointestinal Cancer

Genitourinary Cancers

Global Oncology

Gynecologic Oncology

Head & Neck Cancers

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Mantle Cell Lymphoma

Melanoma & Skin Cancer

Multiple Myeloma

Myeloproliferative Neoplasms

Neoadjuvant HER2+

Non-Hodgkin Lymphoma

Oncology Nursing News

Ovarian Cancer

Pediatric Oncology

Precision Medicine in Oncology®

Prostate Cancer

Sarcomas/TGCT

Supportive Care

Urothelial Cancer

Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival  outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.



Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer

Lifileucel achieved safety and efficacy irrespective of the number of aldesleukin doses administered to patients with advanced melanoma.

Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received

S. Vincent Rajkumar, MD, previews his top 5 abstracts in multiple myeloma ahead of the 2022 ASH Annual Meeting.

Rajkumar Previews CAR-T Updates, Elranatamab Findings in Multiple Myeloma Ahead of ASH 2022

Palbociclib plus fulvestrant did not elicit a progression-free survival benefit vs fulvestrant alone in patients with estrogen receptor–positive/HER2-negative breast cancer who had progressed on prior treatment with a CDK4/6 inhibitor and aromatase inhibitor.

Palbociclib Plus Fulvestrant Fails to Improve PFS in ER+/HER2- Breast Cancer After Progression on a CDK4/6 inhibitor 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Thoracic Night Live

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

OncologyLive

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

Articles

joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

, and now serves as the main digital news writer for 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

2023 nominations are open for Giants of Cancer Care® 

In-person and virtual events just for HCPs

OncClub: Join the Chat on Trending Trials in Cancer

Register | New Options for Advanced HCC

Specialty

®'s Pipeline Report is a collection of news articles and video interviews on emerging agents that are moving through the oncology pipeline. Much of the news comes from biotech companies with novel cancer drugs in their earliest stages, as well as business acquisitions and mergers. The Pipeline Report features innovative therapies being explored across all malignancies.

Pipeline Report Archive

Pipeline Report: April 2022

Pipeline Report: April 2022

Pipeline Report: April 2022

Latest Conference Coverage